Type the code from the image
A Randomized Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with bevacizumab (Avastin) or cetuximab, or with the combination of bevacizumab and cetuximab for patients with untreated metastatic (spread) adenocarcinoma of the colon or rectum.
The purpose of this trial is to determine if the addition of cetuximab to FOLFIRI or FOLFOX chemotherapy with and without bevacizumab prolongs survival compared to FOLFIRI or FOLFOX with bevacizumab in patients with untreated locally advanced or metastatic colorectal cancer who have K-ras wild type tumors.
Patients receiving their doctor’s choice of FOLFOX or FOLFIRI will be randomized to bevacizumab or cetuximab. Cetuximab is supplied at no charge.
Basic Eligibility Criteria:
If you would like information about enrolling into a clinical trial at El Camino Hospital, please contact:
Clinical Research Coordinator
Fogarty Clinical Research